Shares of Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $12.76 and last traded at $12.6420, with a volume of 111559 shares traded. The stock had previously closed at $11.81.
Wall Street Analyst Weigh In
Several brokerages recently weighed in on IMMX. Lifesci Capital started coverage on Immix Biopharma in a research note on Wednesday, June 17th. They issued an “outperform” rating and a $19.00 price target for the company. HC Wainwright increased their price target on Immix Biopharma from $20.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Needham & Company LLC began coverage on Immix Biopharma in a report on Wednesday, July 22nd. They issued a “buy” rating and a $21.00 price objective on the stock. Citigroup restated a “market outperform” rating on shares of Immix Biopharma in a research report on Friday, August 14th. Finally, Bank of America assumed coverage on Immix Biopharma in a research note on Thursday, June 18th. They set a “buy” rating and a $27.00 target price for the company. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Immix Biopharma has an average rating of “Moderate Buy” and an average target price of $21.29.
Get Our Latest Stock Report on Immix Biopharma
Immix Biopharma Stock Performance
Immix Biopharma (NASDAQ:IMMX – Get Free Report) last issued its earnings results on Friday, August 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). Equities research analysts expect that Immix Biopharma, Inc. will post -0.74 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Immix Biopharma
Several institutional investors and hedge funds have recently bought and sold shares of IMMX. LGT Fund Management Co Ltd. grew its position in Immix Biopharma by 233.3% in the first quarter. LGT Fund Management Co Ltd. now owns 416,594 shares of the company’s stock worth $3,795,000 after acquiring an additional 291,594 shares during the period. Janus Henderson Group PLC raised its position in Immix Biopharma by 22.5% in the first quarter. Janus Henderson Group PLC now owns 4,802,002 shares of the company’s stock valued at $43,698,000 after purchasing an additional 880,434 shares during the period. Eventide Asset Management LLC purchased a new stake in Immix Biopharma in the fourth quarter valued at $13,331,000. Sei Investments Co. lifted its stake in shares of Immix Biopharma by 100.0% in the 1st quarter. Sei Investments Co. now owns 147,140 shares of the company’s stock valued at $1,340,000 after purchasing an additional 73,570 shares during the last quarter. Finally, Blue Owl Capital Holdings LP acquired a new position in shares of Immix Biopharma in the 4th quarter valued at $5,158,000. 11.26% of the stock is currently owned by institutional investors and hedge funds.
Immix Biopharma Company Profile
Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.
The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.
Featured Articles
- Five stocks we like better than Immix Biopharma
- Datavault AI Locks Down CyberCatch in $94M Security Rollup
- Quantum Stocks Are Starting to Choose Sides: Should Investors Do the Same?
- AeroVironment Hit a Bottom in Q2—Can It Take Flight in Q3?
- The Pre-IPO Playbook: How to Cash in on Anthropic Before the Bell
Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
